Loading cart...
Labedra 20 Mg (Vardenafil)
Medically reviewed by Sanjay Gangani, B.Pharm, CMO & Pharmacist
| Active Ingredient | Vardenafil |
|---|---|
| Indication | Erectile Dysfucntion |
| Manufacturer | Sozin Flora Pharma LLP |
| Strength:- | 20mg |
| Packaging | 10 tablets in 1 strip |
Labedra 20 Mg (Vardenafil) | ||||
|---|---|---|---|---|
| Pack Size | Price | Quantity | Add To Cart | |
| 60 Tablet/s | $90 | |||
| 90 Tablet/s | $128 | |||
| 120 Tablet/s | $165 | |||
What is Labedra 20 mg
Product identity
| Field | Detail |
| Brand name | Labedra 20 mg |
| Generic name | Vardenafil (as vardenafil hydrochloride) |
| Strength | 20 mg per tablet |
| Drug class | PDE-5 inhibitor |
| Primary use | Erectile dysfunction in adult men |
| Dosage form | Film-coated oral tablet |
| Pack stated on listings | 10 tablets per strip |
| Brand owner claimed | RSM Enterprises, Chandigarh (unverified licence) |
| Published licence number | None found in public records |
| Regulated pharmacy listing | None found in India |
| Legal status in India | Prescription only, Schedule H |
| ATC code | G04BE09 (vardenafil) |
Reference labels used for all clinical content
| Label | Regulator | Role in this page |
| Vardenafil hydrochloride tablets, Macleods | US FDA | Dose caps, QT warning, strengths |
| Vardenafil 20 mg film-coated tablets | MHRA, via the eMC | Contraindications, adverse reactions, pharmacokinetics |
How it works (mechanism of action)
The chain of events
Key pharmacokinetics
| Parameter | Value from the reference label |
| Median time to peak level | About 60 minutes when fasted |
| Peak range | 30 to 120 minutes in 90% of men |
| Earliest reported peak | As early as 15 minutes in some men |
| Terminal half-life | About 4 to 5 hours |
| Absolute oral bioavailability | About 15% |
| Effect of a 57% fat meal | Peak delayed about 1 hour |
| Peak concentration after that meal | Reduced by about 20% |
| Total exposure after that meal | Unchanged |
Dosage guide
Figures below are from the reference labels. Only a prescriber may set your dose.
| Patient group or situation | Starting dose | Maximum dose | Maximum frequency |
| Adult man, no complicating factor | 10 mg | 20 mg | Once in 24 hours |
| Adult man, dose felt too strong | 5 mg | 20 mg | Once in 24 hours |
| Age 65 years or over | 5 mg considered | 20 mg with care | Once in 24 hours |
| Mild liver impairment, Child-Pugh A | 5 mg considered | 20 mg | Once in 24 hours |
| Moderate liver impairment, Child-Pugh B | 5 mg | 10 mg | Once in 24 hours |
| Severe liver impairment, Child-Pugh C | Do not use | Contraindicated | Not applicable |
| Mild or moderate kidney impairment | No adjustment | 20 mg | Once in 24 hours |
| Severe kidney impairment, CrCl under 30 | 5 mg considered | 20 mg | Once in 24 hours |
| Dialysis-dependent kidney failure | Do not use | Contraindicated | Not applicable |
| Stable on an alpha-blocker | 5 mg | Per prescriber | Once in 24 hours |
| On ritonavir or cobicistat | 2.5 mg | 2.5 mg | Once in 72 hours |
| On clarithromycin or atazanavir | 2.5 mg | 2.5 mg | Once in 24 hours |
| On erythromycin | 5 mg | 5 mg | Once in 24 hours |
| Women of any age | Not indicated | Not applicable | Not applicable |
| Anyone under 18 years | Not indicated | Not applicable | Not applicable |
The two label positions differ on protease inhibitors
| Drug | US label position | EU label position |
| Ritonavir | Cap at 2.5 mg per 72 hours | Contraindicated |
| Indinavir | Cap at 2.5 mg per 24 hours | Contraindicated |
| Oral ketoconazole | Cap at 2.5 mg or 5 mg by dose | Contraindicated over age 75 |
| Oral itraconazole | Cap at 2.5 mg or 5 mg by dose | Contraindicated over age 75 |
How to take it
Missed dose
Precautions
Absolute contraindications
Conditions to disclose to your doctor
| Condition | Why it matters |
| Congenital QT prolongation | The US label says to avoid vardenafil |
| Taking amiodarone or sotalol | Class III antiarrhythmic; avoid |
| Taking quinidine or procainamide | Class 1A antiarrhythmic; avoid |
| Any heart or blood vessel disease | Sexual activity carries cardiac risk |
| Low or unstable blood pressure | Risk of fainting |
| Taking any blood pressure medicine | Added blood pressure fall |
| Taking an alpha-blocker for prostate | Start vardenafil at 5 mg only |
| Liver disease of any severity | Dose is reduced or the drug avoided |
| Kidney disease or dialysis | Dose is reduced or the drug avoided |
| Sickle cell anaemia | Predisposes to priapism |
| Multiple myeloma or leukaemia | Predisposes to priapism |
| Penile deformity or Peyronie disease | Needs assessment first |
| Any bleeding disorder | No safety data exist |
| Active peptic ulcer | No safety data exist |
| Any eye or retinal disorder | Rare visual effects are reported |
| Sudden hearing loss in the past | Reported with PDE-5 inhibitors |
| Any CYP3A4 inhibitor medicine | Dose caps may apply |
| Any recreational drug use | Poppers are an absolute contraindication |
Food and drink precautions
Before-use safety checklist
Common and less common side effects
| Frequency | Side effect | What to do |
| Very common | Headache | Usually mild; report if severe |
| Common | Dizziness | Sit down; avoid driving |
| Common | Flushing of the face | Settles without treatment |
| Common | Blocked or stuffy nose | Settles within hours |
| Common | Indigestion or dyspepsia | Take with a light meal |
| Uncommon | Visual disturbance | Stop and seek advice |
| Uncommon | Sleep disturbance | Report to your prescriber |
| Uncommon | Drowsiness | Do not drive |
| Uncommon | Pins and needles | Report if persistent |
| Uncommon | Ringing in the ears | Report promptly |
| Uncommon | Vertigo | Report promptly |
| Uncommon | Palpitations | Report to your prescriber |
| Uncommon | Fast heart rate | Report to your prescriber |
| Uncommon | Breathlessness | Seek medical advice |
| Uncommon | Nausea or vomiting | Usually short-lived |
| Uncommon | Diarrhoea | Keep hydrated |
| Uncommon | Dry mouth | Sip water |
| Uncommon | Rash or skin redness | Report before the next dose |
| Uncommon | Back pain or muscle ache | Usually settles in a day |
| Uncommon | Prolonged or increased erection | Seek advice if over four hours |
| Uncommon | Feeling generally unwell | Report to your prescriber |
| Rare | Fainting | Stop the drug; seek advice |
| Rare | Seizure | Emergency care |
| Rare | Memory loss | Seek medical assessment |
| Rare | Transient ischaemic attack | Emergency care |
| Rare | Heart attack | Emergency care |
| Rare | Ventricular tachyarrhythmia | Emergency care |
| Rare | Angina | Emergency care |
| Rare | Low or high blood pressure | Seek medical assessment |
| Rare | Priapism | Emergency care within four hours |
| Rare | Nosebleed | Apply pressure; report if heavy |
| Rare | Anxiety | Report to your prescriber |
| Rare | Light sensitivity of the skin | Avoid strong sun |
| Rare | Chest pain | Emergency care |
| Not known | NAION, a sudden optic nerve event | Stop and seek care immediately |
| Not known | Central serous chorioretinopathy | Stop and seek eye care |
| Not known | Sudden deafness | Stop and seek care immediately |
| Not known | Sudden death | Reported in surveillance data |
| Not known | Bleeding into the brain | Emergency care |
| Not known | Stevens-Johnson syndrome | Emergency care |
| Not known | Blood in urine or semen | Seek medical assessment |
| Not known | Bleeding from the penis | Seek medical assessment |
Drug interactions – avoid with
Never combine
| Drug or group | Effect | Status |
| Glyceryl trinitrate, any form | Severe blood pressure fall | Contraindicated |
| Isosorbide mononitrate or dinitrate | Severe blood pressure fall | Contraindicated |
| Nicorandil | Nitric oxide donor effect | Contraindicated |
| Sodium nitroprusside | Nitric oxide donor effect | Contraindicated |
| Amyl nitrite, poppers | Severe blood pressure fall | Contraindicated |
| Riociguat | Symptomatic hypotension | Contraindicated |
| Ritonavir | Large rise in vardenafil level | Contraindicated in the EU label |
| Indinavir | Large rise in vardenafil level | Contraindicated in the EU label |
| Another PDE-5 inhibitor | Duplicated effect, added risk | Do not combine |
Use only with a reduced dose or specialist advice
| Drug or group | Effect | Action |
| Cobicistat | Potent CYP3A4 inhibition | Cap at 2.5 mg per 72 hours |
| Saquinavir or atazanavir | Potent CYP3A4 inhibition | Cap at 2.5 mg per 24 hours |
| Clarithromycin | Potent CYP3A4 inhibition | Cap at 2.5 mg per 24 hours |
| Ketoconazole 400 mg daily | Potent CYP3A4 inhibition | Cap at 2.5 mg per 24 hours |
| Itraconazole 400 mg daily | Potent CYP3A4 inhibition | Cap at 2.5 mg per 24 hours |
| Ketoconazole 200 mg daily | CYP3A4 inhibition | Cap at 5 mg per 24 hours |
| Itraconazole 200 mg daily | CYP3A4 inhibition | Cap at 5 mg per 24 hours |
| Erythromycin | CYP3A4 inhibition | Cap at 5 mg per 24 hours |
| Tamsulosin or alfuzosin | Additive blood pressure fall | May be given at any time |
| Terazosin and other alpha-blockers | Additive blood pressure fall | Separate doses by about 6 hours |
| Any antihypertensive medicine | Additive blood pressure fall | Monitor and report |
| Class 1A antiarrhythmics | Added QT risk | Avoid the combination |
| Class III antiarrhythmics | Added QT risk | Avoid the combination |
| Grapefruit juice | CYP3A4 inhibition | Avoid around a dose |
Always disclose
Emergency warning signs
Call emergency services or go to hospital
| Warning sign | Possible cause |
| Erection lasting more than four hours | Priapism; tissue damage risk |
| Painful erection that will not subside | Priapism |
| Chest pain during or after sex | Angina or heart attack |
| Sudden severe breathlessness | Cardiac or pulmonary event |
| Fainting or near-fainting | Severe hypotension |
| Irregular or racing heartbeat | Arrhythmia |
| Sudden loss of vision in one or both eyes | NAION |
| Sudden blurred or distorted vision | Retinal event |
| Sudden hearing loss or severe tinnitus | Sudden sensorineural deafness |
| Sudden one-sided weakness or slurred speech | Stroke or TIA |
| Seizure | Rare neurological reaction |
| Swollen lips, tongue, face or throat | Angioedema |
| Widespread blistering rash with fever | Stevens-Johnson syndrome |
| Bleeding from the penis | Urological emergency |
About the four-hour rule
Why choose this medicine
This section is written about vardenafil 20 mg, the molecule and strength.
Clinical reasons a prescriber may select vardenafil 20 mg
How vardenafil differs from the alternatives
| Point of difference | What it means in practice |
| Half-life about 4 to 5 hours | A shorter window than long-acting options |
| Explicit congenital QT warning | Needs a cardiac history before use |
| Strict CYP3A4 dose-cap table | Many common drugs force a lower strength |
| Four marketed strengths | Allows 2.5 mg and 5 mg where required |
| Food only delays onset | Total effect is not lost after a meal |
A verifiable alternative if you want a regulated Indian brand
Honest limitations
Storage instructions
| Instruction | Detail |
| Temperature | Store below 30 degrees Celsius |
| Humidity | Keep in a cool, dry place |
| Light | Protect from direct sunlight |
| Container | Keep tablets in the original blister strip |
| Bathroom storage | Avoid; humidity degrades tablets |
| Refrigeration | Not required; do not freeze |
| Children | Store well out of sight and reach |
| Expiry | Do not use after the printed expiry date |
| Damaged tablets | Discard chipped, soft or discoloured tablets |
| Unlabelled tablets | Never take a loose tablet with no strip |
| Disposal | Return unused tablets to a pharmacy |
| Sharing | Never share with another person |
A storage caution specific to this product

Reviews
There are no reviews yet.